Clinically significant prostate cancer (csPCa) is the focus of clinical diagnosis and treatment of prostate cancer (PCa). The current standard for diagnosing csPCa in men at risk relies on a transrectal (and in some instances transperineal) ultrasound‐guided biopsy (TRUS‐GB) that is blind to the location of cancer, leading to false‐negative csPCa diagnoses. Over the past decade, PSMA PET/CT imaging–targeted prostate biopsy (PSMA PET/CT‐TB), which obtains tissue samples from a defined suspicious area, has emerged as a promising solution for improving csPCa detection. Its feasibility and higher csPCa diagnostic value have been reported by a few case reports and studies. The current manuscript will review this latest targeted prostate puncture technology, summarize the existing applications of PSMA PET/CT‐TB, including technical considerations, and discuss the advantages and challenges of each technique. [ABSTRACT FROM AUTHOR]